AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00815100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
Trial: NCT02522598
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water for injection
Trial: NCT00604032
Drug: Atralin (tretinoin) Gel, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
Trial: NCT00982930
Drug: Tobramycin inhalation powder
RxNorm normalized name: Tobramycin Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin inhalation powder, 112 mg (4 capsules of 28 mg), inhalation capsules, b.i.d.
Trial: NCT01044446
Drug: glucose-based peritoneal dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: original exchange frequency
Trial: NCT00888069
Drug: CTAP101 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral administration
Trial: NCT00888069
Drug: CTAP101 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV injection
Trial: NCT02995122
Drug: BAY987516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z43-090)
Trial: NCT02995122
Drug: SPF Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Trial: NCT04671069
Drug: MGL-3196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
Trial: NCT00255957
Drug: Hydroxy Ethyl Starch administration to stroke patients
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03846102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0,9% for injection/infusion.
Trial: NCT03846102
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 milligram tablet
Trial: NCT02775955
Drug: RX0041
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT02170025
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo tid.
Trial: NCT01435863
Drug: SP-02L (darinaparsin for injection)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Trial: NCT01435863
Drug: SP-02L (darinaparsin for injection)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Trial: NCT01435863
Drug: SP-02L (darinaparsin for injection)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Trial: NCT01389193
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
Trial: NCT01263314
Drug: MK-8266
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, 0.1 mg potency
Trial: NCT01263314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules to match MK-8266 capsules
Trial: NCT00545480
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 12 months (with feedback)
Trial: NCT00545480
Drug: ibandronate [Bonviva/Boniva]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg po monthly for 12 months (without feedback)
Trial: NCT00559416
Drug: Cell Transfer
RxNorm normalized name: SET,TRANSFER
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02465255
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02465255
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03167541
Drug: Test
RxNorm normalized name: Testro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RB naproxen sodium tablets (2x220mg)
Trial: NCT03167541
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aleve naproxen sodium tablets (2x220mg)
Trial: NCT03862495
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1g administered as a single oral dose
Trial: NCT03933280
Drug: Benoxinate Hydrochloride 0.4% Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
Trial: NCT01472991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be taken once daily for 4 weeks
Trial: NCT00520637
Drug: EZN-2208
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02563925
Drug: HER2 directed therapy
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03745300
Drug: SIMVASTATIN
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scaling and Root Planing (SRP) followed by placement of simvastatin gel
Trial: NCT03745300
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and Root Planing (SRP) followed by placement of placebo gel
Trial: NCT00947843
Drug: aspirin + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01429454
Drug: Omega-3 Long Chain Fatty Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
Trial: NCT01429454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
Trial: NCT01690884
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
Trial: NCT00909519
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg bid
Trial: NCT00909519
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01148693
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg per 10ml of contrast media
Trial: NCT01148693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distilled water
Trial: NCT05405244
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules, orally administered once
Trial: NCT02219711
Drug: MGCD516
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases. MGCD516 capsules will be taken with water.
Trial: NCT02879916
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject 3ml of NaCl 0.9% into the stellate ganglion area
Trial: NCT01652937
Drug: BIIB057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03530202
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (\~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
Trial: NCT01575899
Drug: Clarithromycin-Amoxicillin
RxNorm normalized name: AMOXICILLIN/CLARITHROMYCIN/VONOPRAZAN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
Trial: NCT02261883
Drug: IV Remodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
Trial: NCT02261883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
Trial: NCT04460066
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.
Trial: NCT02708394
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control
Trial: NCT01204996
Drug: CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
Trial: NCT01027013
Drug: placebo eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill one drop in each eye four times daily for 12 weeks.
Trial: NCT02205398
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03751423
Drug: IV Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
Trial: NCT03751423
Drug: PO Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
Trial: NCT03751423
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
Trial: NCT00976248
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day
Trial: NCT02278081
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the lansoprazole placebo will be taken orally.
Trial: NCT02905916
Drug: PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03246750
Drug: B-MAD chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-MAD chemotherapy
Trial: NCT03490032
Drug: [68Ga]-PSMA-R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radio-labelled PSMA ligand
Trial: NCT03618602
Drug: Bisthianostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
Trial: NCT01730287
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Hydroxide paste applied.
Trial: NCT03345992
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
Trial: NCT03289871
Drug: Loceryl 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01100645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excipient
Trial: NCT00648570
Drug: Lexapro® Tablets (20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg, single dose fasting
Trial: NCT04213508
Drug: Isotonic Saline ( 0.9% Sodium Chloride Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time) . So, in total 500 ml of 0.9% Sodium Chloride (NaCl) saline will be used daily for 1 month .
Trial: NCT04213508
Drug: Hypertonic Saline ( 3% Sodium Chloride Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% Sodium Chloride (NaCl) saline will be used as nasal irrigation for two groups. (first groups 2 times per day and second group 5 times per day ). Each time, amount of 50 ml of saline will be used in each nostril ( 100 ml for both nostrils per time). So, in total 200 ml of 3% Sodium Chloride (NaCl) saline will be used daily for 1 month .
Trial: NCT00848770
Drug: Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.
Trial: NCT00848770
Drug: manipulation of SAP
RxNorm normalized name: Bambusa vulgaris sap extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol or NPS or NOR
Trial: NCT01808352
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
Trial: NCT00425074
Drug: SR-ASA
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow release acetylsalicylic acid 150 mg
Trial: NCT03609489
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
Trial: NCT01261260
Drug: Uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram tablets BID for 7 days
Trial: NCT03983460
Drug: Optimized TCS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
Trial: NCT02271009
Drug: AllerT
RxNorm normalized name: AllerTan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrafast immunotherapy
Trial: NCT02271009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo control
Trial: NCT01248403
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAD001 10mg (2 x5 mg tablets / day) d1-d28
Trial: NCT00381719
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg Capsule twice daily for 4 weeks
Trial: NCT00381719
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Capsule twice daily for 4 weeks
Trial: NCT00381719
Drug: AGN 203818
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Capsule twice daily for 4 weeks
Trial: NCT00381719
Drug: placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule twice daily for 4 weeks
Trial: NCT02312115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT00168909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo once daily, oral, for 3 years
Trial: NCT00649558
Drug: Actos® Tablets 45 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45mg, single dose fasting
Trial: NCT03657810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching CL-108
Trial: NCT00054158
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03779633
Drug: Linoladiol Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks
Trial: NCT02006498
Drug: Sillymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
Trial: NCT02006498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule with same appearances as study drug
Trial: NCT05621590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules filled with stevia sweetened powder
Trial: NCT01452724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
Trial: NCT01452724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
Trial: NCT00812604
Drug: Ping On Ointment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ping On Ointment
Trial: NCT02268136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02701179
Drug: Lignocaine 1% concentration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02701179
Drug: Lignocaine 2% concentration solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03617913
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02232594
Drug: Berodual®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03771443
Drug: experimental gluten free toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
Trial: NCT00724815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP101 Placebo iontophoretic transdermal patch
Trial: NCT01709214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
Trial: NCT01226706
Drug: Botulinum Toxins, Type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
Trial: NCT01226706
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
Trial: NCT00345501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end